Drug intelligence / Profile preview

TB-100

Development stage: Preclinical
Lead developer: Therabest
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Subcutaneous, Intramuscular

Overview

TB-100 is an induced pluripotent stem cell (iPSC)-derived Natural Killer (NK) cell product developed by Therabest. It is being clinically developed as part of a combination therapy for triple-negative breast cancer (TNBC). The therapy aims to overcome limitations of NK cell therapy in solid tumors, such as low persistency and homing, by enhancing the activity, specificity, and persistence of TB-100 at the tumor site.

Other names: iPSC-derived NK cell therapy

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)MICB (Major histocompatibility complex class i-related protein B)IgG Fc (Immunoglobulin G Fc region)TNFRSF10A (Death receptor 4)

Beyond the preview

Go deeper on TB-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-100.

Explore the full profile